News coverage about BIOLASE (NASDAQ:BIOL) has been trending somewhat positive on Sunday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BIOLASE earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media stories about the medical technology company an impact score of 46.9614544394612 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of BIOLASE stock remained flat at $$0.44 on Friday. The company had a trading volume of 49,957 shares, compared to its average volume of 133,569. BIOLASE has a one year low of $0.28 and a one year high of $1.45. The stock has a market capitalization of $44.79, a P/E ratio of -1.51 and a beta of 1.81.
BIOLASE (NASDAQ:BIOL) last posted its quarterly earnings data on Wednesday, March 14th. The medical technology company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). BIOLASE had a negative return on equity of 67.04% and a negative net margin of 35.91%. The firm had revenue of $12.63 million during the quarter.
BIOLASE Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.